Prominent speakers from Latin America and around the world will give their views on the latest topics in regulation at the DIA’s 5th Latin American Regulatory Conference (LARC) 2013
, to be held in Bogota, Colombia in one week’s time, from May 15-16.
The event will focus on “Pharma-Co-Vergence” – the act of achieving pharmaceutical regulatory convergence through stakeholders’ collaboration – highlighting the truly collaborative spirit of this multidisciplinary global conference.
Representatives will be attending from Colombia (INVIMA), Ecuador and Guatemala (MoH), Chile (ISPCH), Brazil (ANVISA), the USA (FDA), Canada (Health Canada), Spain (AEMPS), Mexico (COFEPRIS), and Peru (DIGEMID). Global organizations including the Pan American Health Organization and the World Health Organization will also be taking part
The many high-profile speakers include:
- Elizabeth Armstrong González, Head of the Instituto de Salud Publica de Chile (ISPCH), Agencia Nacional de Medicamentos (ANAMED) in Chile, and Jose Daniel Peña Ruz, QF, Regional Advisor, Medicines and Health Technologies PAHO/WHO, both giving their views on regional and global convergence
- Laura Gomes Castanheira, Manager of Research and Clinical Trials, COPEM/ANVISA, Government of Brazil, speaking during the session on “Risk Based Approach to Inspections”
- Claudia Vaca, MD, Advisor on Medicines, Ministry of Health and Social Protection, Government of Colombia, speaking on the latest issues in pharmacovilgilance
- Hans Vasquez, MD, Clinical Review Coordinator, Direccion General de Medicamentos Insumos y Drogas (DIGEMID), Ministerio de Salud, Government of Peru participating in a session on “Biosimilar Products/Generics and Bioequivalence”
- Nazly Cuevas Melendez, MD, Medicines for Human Use Department, Clinical Trials Division Spanish, Agency Medicine and Sanitary Products (AEMPS), Government of Spain giving her views on “Clinical Studies and Bioethics”
For more information, or to register, visit www.diahome.org/LARC2013.
DIA is the global connector in the life sciences product development process. Our association of more than 18,000 members builds productive relationships by bringing together regulators, innovators and influencers to exchange knowledge and collaborate in an impartial setting. DIA’s network creates unparalleled opportunities for the exchange of knowledge and has the interdisciplinary experience to prepare for future developments. The dedicated efforts of DIA staff, members and speakers enable DIA to provide a comprehensive catalogue of conferences, workshops, training courses, scientific publications and educational materials. DIA is a global community representing thousands of stakeholders working together to bring safe and effective products to patients. DIA is an independent, nonprofit organization with its global center in Washington, D.C., USA; regional offices covering North and South America (Horsham, Penn., USA); Europe, North Africa and the Middle East (Basel, Switzerland); and Japan (Tokyo), India (Mumbai) and China (Beijing). For more information, visit www.diahome.org